Shahrooz Ghaderi
1,2,3, Neda Alidadiani
1*, Jafar Soleimani Rad
4, Hamid Reza Heidari
5, Nafi Dilaver
6, Behzad Mansoori
1, Reza Rhabarghazi
7,8, Rezayat Parvizi
9, Vahid Khaze Shahgoli
1, Behzad Baradaran
1*1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Student research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Department of Anatomy, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
6 Swansea University Medical School, Swansea University, Swansea, UK.
7 Stem cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
8 Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
9 Department of Cardiothoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
Purpose: Cardiovascular gene therapy is a
sophisticated approach, thanks to the safety of vectors, stable transgene expression,
delivery method, and different layers of the heart. To date, numerous expression
vectors have been introduced in biotechnology and biopharmacy industries in relation
to genetic manipulation. Despite the rapid growth of these modalities, they must
be intelligently designed, addressing the cardiac-specific transgene expression
and less side effects. Herein, we conducted a pilot project aiming to design a cardiac-specific
hypoxia-inducible expression cassette.
Methods: We explored a new approach to design
an expression cassette containing cardiac specific enhancer, hypoxia response elements
(HRE), cardiac specific promoter, internal ribosome entry site (IRES), and beta
globin poly A sequence to elicit specific and inducible expression of the gene of
interest. Enhanced green fluorescent protein (eGFP) was sub-cloned by BglII
and NotI into the cassette. The specificity and inducible expression of the
cassette was determined in both mouse myoblast C2C12 and mammary glandular tumor
4T1 as ‘twin’ cells. eGFP expression was evaluated by immunofluorescence microscope
and flow cytometry at 520 nm emission peak.
Results: Our data revealed that the designed
expression cassette provided tissue specific and hypoxia inducible (O2<1%)
transgene expression.
Conclusion: It is suggested that cardiac-specific
enhancer combined with cardiac-specific promoter are efficient for myoblast specific
gene expression. As well, this is for the first time that HRE are derived from three
well known hypoxia-regulated promoters. Therefore, there is no longer need to overlap
PCR process for one repeated sequence just in one promoter.